HC Wainwright Issues Pessimistic Outlook for SRTS Earnings

Key Points

• HC Wainwright has significantly revised its earnings estimates for Sensus Healthcare, predicting a Q3 2025 EPS of ($0.12), down from the previous estimate of ($0.02).
• The company recently reported a loss of ($0.06) EPS for the previous quarter, missing the consensus estimate of $0.01 by ($0.07), along with lower revenue than expected at $7.32 million.
• Despite downgrades from other analysts, HC Wainwright maintains a "Buy" rating on Sensus Healthcare with a target price of $8.00.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2025 earnings estimates for Sensus Healthcare in a research report issued on Tuesday, August 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.12) per share for the quarter, down from their prior forecast of ($0.02). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.01 EPS.

SRTS has been the subject of a number of other research reports. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd. Finally, Maxim Group cut their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $8.00.

Sensus Healthcare Trading Down 1.1%

Shares of Sensus Healthcare stock traded down $0.0350 during trading hours on Thursday, reaching $3.2750. The stock had a trading volume of 64,709 shares, compared to its average volume of 190,909. The stock's 50 day moving average is $4.65 and its 200 day moving average is $4.83. The firm has a market capitalization of $53.84 million, a PE ratio of -54.58 and a beta of 1.34. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.

Institutional Trading of Sensus Healthcare

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in Sensus Healthcare during the 4th quarter valued at about $27,000. Barclays PLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at about $35,000. Larson Financial Group LLC acquired a new position in Sensus Healthcare in the 1st quarter valued at about $26,000. BNP Paribas Financial Markets acquired a new position in Sensus Healthcare in the 4th quarter valued at about $47,000. Finally, Vise Technologies Inc. acquired a new position in Sensus Healthcare in the 2nd quarter valued at about $52,000. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.